Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The product, a biosimilar to Neulasta, is developed and manufactured by Biocon Biologics, parent entity of Biocon Biologics UK PLC, with Global Regulatory Partners Japan serving as the marketing authorization holder on behalf of Biocon. Sandoz K.K. shall exclusively promote, sell, and distribute the product in Japan.
Pegfilgrastim is a prescription injection used to lower the risk of infection in people receiving strong cancer chemotherapy or those exposed to high doses of radiation.
'This approval further strengthens Biocon’s portfolio of biosimilar products in Japan and reaffirms the company’s commitment to increasing patient access to high-quality and affordable medications globally,' the company said in a statement.
Biocon is India’s leading biopharma company. It is fully integrated and delivers biopharma solutions ranging from discovery to development and commercialisation. It has diversified revenue streams covering biosimilars, contract research, small molecules and APIs.
The company had reported 355% jump in consolidated net profit to Rs 141 crore in Q1 FY27 from Rs 31 crore in Q1 FY26. Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.
The scrip shed 0.28% to currently trade at Rs 408.85 on the BSE.
Biocon's subsidiary in the United States has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek® 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek® 90 mg/ml single-dose prefilled autoinjector.
Yesintek® was originally approved by the U.S. FDA on 29 November 2024. The Yesintek® single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.
Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn's disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affects tens of thousands of Americans.
Yesintek was originally approved by the U.S. FDA on 29 November 2024.
The Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.
Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn’s disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affects tens of thousands of Americans.
'This supplemental approval enhances Biocon’s comprehensive portfolio of immunology products in the United States and reaffirms the company’s commitment to improving access to affordable medicines for patients around the world,' the company said in a statement.
The scrip rose 0.30% to currently trade at Rs 413.35 on the BSE.
Shares of Life Insurance Corporation of India (LIC) are banned from F&O trading on 6 August 2026.
New listing:
MV Electrosystems will make its stock market debut today. The Rs 290-crore IPO was offered in a price band of Rs 400–425 per share. The issue received bids for 75.30 crore shares against 39.87 lakh shares on offer, resulting in an overall subscription of 188.85 times.
Juniper Green Energy is also set to debut on the bourses today. The company's Rs 1,800-crore IPO, priced in the Rs 214–225 per share band, received bids for 46.96 crore shares against 5.89 crore shares on offer, translating into an overall subscription of 7.97 times.
Earnings Today:
Life Insurance Corporation of India (LIC), Hero MotoCorp, Britannia Industries, Lupin, Samvardhana Motherson International, Apollo Tyres, Blue Star, Fortis Healthcare, Crompton Greaves Consumer Electricals, Bosch Home Comfort India, Premier Energies, NCC, Emcure Pharmaceuticals, EIH, Aegis Logistics, PG Electroplast, Firstsource Solutions, Signatureglobal (India), RateGain Travel Technologies, Campus Activewear will declare their quarterly results later today.
Stocks to Watch:
Aurobindo Pharma reported 28.11% jump in consolidated net profit to Rs 1,056.56 crore in Q1 FY27 compared with Rs 824.75 crore in Q1 FY26. Revenue from operations climbed 16.30% YoY to Rs 9,150.35 crore in Q1 FY27.
PB Fintech (Policy Bazaar)’s consolidated net profit jumped 92.54% to Rs 162.89 crore on 40.08% increase in revenue from operations to Rs 1,888.28 crore in Q1 FY27 over Q1 FY26.
Biocon’s consolidated net profit surged 872.27% to Rs 142.35 crore in Q1 FY27, compared with Rs 36.76 crore in Q1 FY26. Net sales jumped 10% YoY to Rs 4,336 crore in Q1 FY27.
Neuland Laboratories reported 962.37% surge in consolidated net profit to Rs 147.67 crore in Q1 FY27 compared with Rs 13.9 crore posted in year-ago period. Net sales soared 119.16% YoY to Rs 641.58 crore in the quarter ended 30th Jun 2026.
Bikaji Foods International's consolidated net profit edged up 0.4% YoY to Rs 60.14 crore in Q1 FY27, compared with Rs 59.90 crore a year ago. Net sales grew 12.5% YoY to Rs 734.26 crore.
JK Lakshmi Cement reported 29.60% decline in standalone net profit to Rs 106.77 crore in Q1 FY27 from Rs 151.67 crore in Q1 FY26. Net sales rose 9.41% YoY to Rs 1,904.78 crore in Q1 FY27.
Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.
Biopharma (Biosimilars + Generics) revenue grew 17% YoY in the first quarter, driven by momentum from recent biosimilar and generic product launches across key markets. Biosimilars revenue increased 16% YoY to Rs 2,855 crore and Generics revenue increased 21% YoY Rs 760 crore in Q1 FY27.
Services revenue decreased 16% YoY to Rs 736 crore in Q1 FY27 due to continued impact of challenges faced last year.
Net R&D expenses for Q1 FY27 added up to Rs 240 crore, up 17% YoY.
While EBITDA improved by 7% YoY to Rs 902 crore, EBITDA margin remained stable at 21% in the June'26 quarter.
Profit before tax in Q1 FY27 stood at Rs 128 crore, up 32% from Rs 97 crore in Q1 FY26.
The company has recorded a net tax credit of Rs 92 crore for the June'26 quarter. It had reported a net tax outgo of Rs 77 crore in the same period last year.
Kiran Mazumdar-Shaw, executive chairperson, Biocon, said: 'Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation.
A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market.
We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth.'
Biocon announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation* by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws.
Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, “The launch of Yesafili™️ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea®️ 2 mg, advancing access to life-changing medicines for patients around the world.”
Supplies to Europe from this line are expected to begin from Q2FY27.
The block deal witnessed strong participation from domestic and foreign institutional investors. ICICI Prudential Mutual Fund emerged as the largest buyer, acquiring 3.69 crore shares (2.26% stake). HDFC Mutual Fund and Kotak Mahindra Mutual Fund each purchased 1.16 crore shares (0.71% stake), while SBI Mutual Fund acquired 50 lakh shares (0.31% stake). ICICI Prudential Life Insurance bought 25 lakh shares (0.15% stake). Aditya Birla Sun Life Mutual Fund, Franklin Templeton Mutual Fund and Mirae Asset Mutual Fund acquired 18.75 lakh shares (0.12% stake) each, while Tata Mutual Fund purchased 6.26 lakh shares (0.04% stake).
Other investors, including Axis Mutual Fund, UTI Mutual Fund, Mahindra Mutual Fund, IDFC Mutual Fund, HDFC Life Insurance, Bajaj Life Insurance, Norges Bank, Goldman Sachs Bank Europe, Morgan Stanley Asia Singapore, Societe Generale, Vanguard Emerging Markets Shares Index Fund, WhiteOak Capital Mutual Fund, Authum Investment & Infrastructure, Abakkus Growth Fund, Canara Robeco Mutual Fund and Eastspring Investments Asian Low Volatility Equity Fund, each acquired 6.26 lakh shares (0.04% stake). Citigroup Global Markets Singapore and BNP Paribas Arbitrage purchased 7.50 lakh shares (0.05% stake) each.
Mylan's relationship with Biocon began in 2009, when the companies entered into a global collaboration to develop and commercialise biosimilars. The partnership later expanded to generic insulin analogues. Mylan became a shareholder in Biocon in January 2026 after the company issued shares as part of the acquisition of Viatris' stake in Biocon Biologics. The latest transaction marks Mylan's complete exit from Biocon.
As of 30 June 2026, Biocon's promoters held a 44.67% stake in the company, while Mylan owned 5.64%.
Biocon is a global biopharmaceutical company focused on developing affordable therapies for chronic diseases, including diabetes, cancer and autoimmune disorders.
On a consolidated basis, the company's net profit declined 63.4% YoY to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations increased 2.26% YoY to Rs 4,517 crore during the quarter.
Shares of Biocon were down 0.70% at Rs 434.25 on the NSE.